DOP2013000299A - Anticuerpos anti-angptl3 y usos de los mismos - Google Patents
Anticuerpos anti-angptl3 y usos de los mismosInfo
- Publication number
- DOP2013000299A DOP2013000299A DO2013000299A DO2013000299A DOP2013000299A DO P2013000299 A DOP2013000299 A DO P2013000299A DO 2013000299 A DO2013000299 A DO 2013000299A DO 2013000299 A DO2013000299 A DO 2013000299A DO P2013000299 A DOP2013000299 A DO P2013000299A
- Authority
- DO
- Dominican Republic
- Prior art keywords
- diseases
- hangptl3
- disorders
- human
- hypertriglyceridemia
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/455—Nicotinic acids, e.g. niacin; Derivatives thereof, e.g. esters, amides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Diabetes (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Endocrinology (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Emergency Medicine (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Gastroenterology & Hepatology (AREA)
- Child & Adolescent Psychology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Abstract
Se proporciona un anticuerpo totalmente humano o fragmento de fijación de antígeno de un anticuerpo humano que se fija específicamente e inhibe o interfiere con al menos una actividad de la proteína 3 de tipo angiopoyetina humana (hANGPTL3). Los anticuerpos anti-hANGPTL3 humanos son útiles en el tratamiento de enfermedades o trastornos asociados con ANGPTL3, tales como hipertrigliceridemia, hiperlipoproteinemia y dislipidemia, con inclusión de hipertrigliceridemia, hipercolesterolemia, quilomicronemia, etcétera. Adicionalmente, los anticuerpos anti-hANGPTL3 pueden administrarse a un individuo en necesidad de ello para prevenir o tratar enfermedades o trastornos, para los cuales el metabolismo anormal de los lípidos es un factor de riesgo. Tales enfermedades o trastornos incluyen enfermedades cardiovasculares, tales como ateroesclerosis y enfermedades de las arterias coronarias; pancreatitis aguda; esteatohepatitis no alcohólica (NASH); diabetes; obesidad; y análogos.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201161498518P | 2011-06-17 | 2011-06-17 | |
| US201161578309P | 2011-12-21 | 2011-12-21 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DOP2013000299A true DOP2013000299A (es) | 2014-04-15 |
Family
ID=46298728
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DO2013000299A DOP2013000299A (es) | 2011-06-17 | 2013-12-11 | Anticuerpos anti-angptl3 y usos de los mismos |
Country Status (42)
Families Citing this family (55)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AR087329A1 (es) * | 2011-06-17 | 2014-03-19 | Regeneron Pharma | Anticuerpos humanos contra proteina 3 de tipo angiopoietina humana |
| US9255154B2 (en) | 2012-05-08 | 2016-02-09 | Alderbio Holdings, Llc | Anti-PCSK9 antibodies and use thereof |
| AR095196A1 (es) | 2013-03-15 | 2015-09-30 | Regeneron Pharma | Medio de cultivo celular libre de suero |
| WO2017011929A1 (zh) * | 2015-07-17 | 2017-01-26 | 北京大学第一医院 | 检测血清血管生成素样蛋白2含量的物质在制备检测肝脏炎症和纤维化程度产品中的应用 |
| TW202340452A (zh) | 2015-08-04 | 2023-10-16 | 美商再生元醫藥公司 | 補充牛磺酸之細胞培養基及用法 |
| TW201713690A (zh) | 2015-08-07 | 2017-04-16 | 再生元醫藥公司 | 抗ａｎｇｐｔｌ８抗體及其用途 |
| CN108697797A (zh) * | 2016-02-17 | 2018-10-23 | 瑞泽恩制药公司 | 通过施用angptl3的抑制剂治疗或预防动脉粥样硬化的方法 |
| EA201891979A1 (ru) * | 2016-03-03 | 2019-01-31 | Ридженерон Фармасьютикалз, Инк. | Способы лечения пациентов с гиперлипидемией введением ингибитора pcsk9 в комбинации с ингибитором angptl3 |
| PL3439689T3 (pl) * | 2016-04-08 | 2022-01-31 | Regeneron Pharmaceuticals, Inc. | Sposoby leczenia hiperlipidemii inhibitorem angptl8 i inhibitorem angptl3 |
| EP3448426A1 (en) * | 2016-04-28 | 2019-03-06 | Regeneron Pharmaceuticals, Inc. | Methods for treating patients with familial hypercholesterolemia |
| WO2018039499A1 (en) | 2016-08-24 | 2018-03-01 | Regeneron Pharmaceuticals, Inc. | Host cell protein modification |
| JP7133551B2 (ja) | 2016-11-17 | 2022-09-08 | リジェネロン・ファーマシューティカルズ・インコーポレイテッド | 抗ａｎｇｐｔｌ８抗体を用いて肥満を処置する方法 |
| TW201934570A (zh) | 2017-07-06 | 2019-09-01 | 美商雷傑納榮製藥公司 | 供製備糖蛋白之細胞培養方法 |
| WO2019126194A1 (en) | 2017-12-18 | 2019-06-27 | Regeneron Pharmaceuticals, Inc. | Angptl8 assay and uses thereof |
| MX2020006639A (es) | 2017-12-22 | 2020-09-14 | Regeneron Pharma | Sistema y metodo para caracterizar las impurezas de un producto farmaceutico. |
| EP3746471A1 (en) | 2018-01-31 | 2020-12-09 | Regeneron Pharmaceuticals, Inc. | System and method for characterizing size and charge variant drug product impurities |
| TW202311746A (zh) | 2018-02-02 | 2023-03-16 | 美商再生元醫藥公司 | 用於表徵蛋白質二聚合之系統及方法 |
| MX2020008988A (es) | 2018-02-28 | 2020-09-28 | Regeneron Pharma | Sistemas y metodos para la identificacion de contaminantes virales. |
| EP4317959A3 (en) | 2018-03-19 | 2024-03-27 | Regeneron Pharmaceuticals, Inc. | Microchip capillary electrophoresis assays and reagents |
| TW202016125A (zh) | 2018-05-10 | 2020-05-01 | 美商再生元醫藥公司 | 用於定量及調節蛋白質黏度之系統與方法 |
| MX2021002279A (es) | 2018-08-27 | 2021-05-27 | Regeneron Pharma | Uso de espectroscopia raman en la purificacion corriente abajo. |
| CN112601963A (zh) | 2018-08-30 | 2021-04-02 | 瑞泽恩制药公司 | 用于表征蛋白质复合物的方法 |
| WO2020109978A1 (en) * | 2018-11-26 | 2020-06-04 | Novartis Ag | Lpl-gpihbp1 fusion polypeptides |
| TWI747098B (zh) * | 2018-12-21 | 2021-11-21 | 美商美國禮來大藥廠 | 抗angptl3/8複合物抗體及其使用方法 |
| MX2021008589A (es) | 2019-01-16 | 2021-08-11 | Regeneron Pharma | Metodos para identificar tioles libres en proteinas. |
| WO2020185952A1 (en) * | 2019-03-11 | 2020-09-17 | xCella Biosciences, Inc. | Cd27-binding antibodies and uses thereof |
| CN113785203A (zh) | 2019-05-13 | 2021-12-10 | 里珍纳龙药品有限公司 | 改进的竞争性配体结合测定 |
| US20200369760A1 (en) * | 2019-05-24 | 2020-11-26 | Regeneron Pharmaceuticals, Inc. | Stabilized formulations containing anti-angptl3 antibodies |
| CN112062845B (zh) * | 2019-06-10 | 2022-09-02 | 山东博安生物技术股份有限公司 | Angptl3结合片段及其用途 |
| EP3993820A4 (en) * | 2019-07-04 | 2023-08-16 | Cadila Healthcare Limited | VACCINE BASED ON ANGPTL3 FOR THE TREATMENT OF LIVER DISEASES |
| MX2022003438A (es) | 2019-09-24 | 2022-04-19 | Regeneron Pharma | Sistemas y metodos para uso y regeneracion de cromatografia. |
| BR112022009974A2 (pt) | 2019-11-25 | 2022-08-16 | Regeneron Pharma | Métodos de produção de um polímero ou micropartículas revestidas com polímero, para produzir microesferas poliméricas ou revestidas com polímero e para produzir micropartículas, composição de liberação sustentada, micropartículas, e, composição farmacêutica |
| CN110938144B (zh) * | 2019-11-27 | 2022-07-26 | 复旦大学附属儿科医院 | 一种抗angptl3单克隆抗体及其在制备治疗肾病综合征药物中的用途 |
| US11835527B2 (en) | 2020-01-21 | 2023-12-05 | Regeneron Pharmaceuticals, Inc. | Deglycosylation methods for electrophoresis of glycosylated proteins |
| JP2023510787A (ja) * | 2020-01-22 | 2023-03-15 | 江蘇恒瑞医薬股▲ふん▼有限公司 | 抗ａｎｇｐｔｌ３抗体及びその応用 |
| IL300828A (en) | 2020-08-31 | 2023-04-01 | Regeneron Pharma | Asparagine feeding strategies to improve cell culture performance and reduce asparagine sequence variants |
| EP4251128A1 (en) | 2020-11-25 | 2023-10-04 | Regeneron Pharmaceuticals, Inc. | Sustained release formulations using non-aqueous membrane emulsification |
| US20220257707A1 (en) | 2020-12-17 | 2022-08-18 | Regeneron Pharmaceuticals, Inc. | Fabrication of protein-encapsulating microgels |
| CN116761880A (zh) | 2021-01-20 | 2023-09-15 | 瑞泽恩制药公司 | 改进细胞培养物中的蛋白质滴度的方法 |
| EP4302098A1 (en) | 2021-03-03 | 2024-01-10 | Regeneron Pharmaceuticals, Inc. | Systems and methods for quantifying and modifying protein viscosity |
| US20240141029A1 (en) * | 2021-03-05 | 2024-05-02 | Anji Pharmaceuticals Inc. | Methods and compositions for treating sepsis |
| CA3211302A1 (en) | 2021-03-26 | 2022-09-29 | Ross Kenyon | Methods and systems for developing mixing protocols |
| WO2022205021A1 (zh) * | 2021-03-30 | 2022-10-06 | 复旦大学附属儿科医院 | 一种抗angptl3抗体或其抗原结合片段及其制备方法和用途 |
| TW202314240A (zh) | 2021-06-01 | 2023-04-01 | 美商再生元醫藥公司 | 微晶片毛細管電泳分析及試劑 |
| CA3225970A1 (en) * | 2021-07-21 | 2023-01-26 | Jiangsu Hengrui Pharmaceuticals Co., Ltd. | Pharmaceutical composition of anti-angptl3 antibody or antigen binding fragment thereof and its application |
| TW202326138A (zh) | 2021-09-08 | 2023-07-01 | 美商再生元醫藥公司 | 用於定量抗體及其他含Ｆｃ蛋白之高通量及基於質譜之方法 |
| WO2023044139A1 (en) | 2021-09-20 | 2023-03-23 | Regeneron Pharmaceuticals, Inc. | Methods of controlling antibody heterogeneity |
| US20230116199A1 (en) | 2021-10-07 | 2023-04-13 | Regeneron Pharmaceuticals, Inc. | Systems and methods of ph modeling and control |
| CA3230985A1 (en) | 2021-10-07 | 2023-04-13 | Ross BROWNE | Ph meter calibration and correction |
| US20230129265A1 (en) | 2021-10-26 | 2023-04-27 | Regeneron Pharmaceuticals, Inc. | Systems and methods for generating laboratory water and distributing laboratory water at different temperatures |
| CN116284377A (zh) * | 2021-12-21 | 2023-06-23 | 复旦大学 | 抗人血管生成素3纳米抗体及其应用 |
| US20230193271A1 (en) * | 2021-12-22 | 2023-06-22 | Regeneron Pharmaceuticals, Inc. | Treatment Of Kidney Diseases With Angiopoietin Like 3 (ANGPTL3) Inhibitors |
| US20230296559A1 (en) | 2022-03-18 | 2023-09-21 | Regeneron Pharmaceuticals, Inc. | Methods and systems for analyzing polypeptide variants |
| US11780910B1 (en) | 2022-05-02 | 2023-10-10 | Novo Nordisk A/S | Anti-ANGPTL3 antibodies suitable for high concentration compositions and subcutaneous administration |
| CN117603361A (zh) * | 2022-08-22 | 2024-02-27 | 复旦大学附属儿科医院 | 包含angptl3单抗的融合蛋白 |
Family Cites Families (32)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20020035058A1 (en) | 1996-05-15 | 2002-03-21 | The University Of Sheffield | Isopentenyl pyrophosphate isomerase (IPI) and/or prenyl transferase inhibitors |
| US6030831A (en) | 1997-09-19 | 2000-02-29 | Genetech, Inc. | Tie ligand homologues |
| US7070959B1 (en) | 1999-06-08 | 2006-07-04 | Regeneron Pharmaceuticals, Inc. | Modified chimeric polypeptides with improved pharmacokinetic properties |
| US6534088B2 (en) | 2001-02-22 | 2003-03-18 | Skyepharma Canada Inc. | Fibrate-statin combinations with reduced fed-fasted effects |
| MXPA04004609A (es) | 2001-11-16 | 2004-08-12 | Genentech Inc | Composicion que comprende y metodo para utilizar angptl3 de proteina 3 como angiopoyetina. |
| EP2322203A3 (en) | 2002-10-29 | 2011-07-27 | Genentech, Inc. | Compositions and methods for the treatment of immune related diseases |
| US20040101920A1 (en) | 2002-11-01 | 2004-05-27 | Czeslaw Radziejewski | Modification assisted profiling (MAP) methodology |
| JP2005080508A (ja) | 2003-09-04 | 2005-03-31 | Sankyo Co Ltd | 脂質代謝改善剤の試験方法 |
| WO2005103081A2 (en) | 2004-04-20 | 2005-11-03 | Genmab A/S | Human monoclonal antibodies against cd20 |
| JP2008532516A (ja) | 2005-03-11 | 2008-08-21 | ジェネンテック・インコーポレーテッド | 遺伝子破壊、組成物、およびそれに関連する方法 |
| JP5489465B2 (ja) | 2005-12-16 | 2014-05-14 | リジェネロン・ファーマシューティカルズ・インコーポレイテッド | Ｄｌｌ４アンタゴニストによって腫瘍増殖を阻害する治療方法 |
| RS52643B (en) | 2006-06-02 | 2013-06-28 | Regeneron Pharmaceuticals Inc. | HIGH AFINITY ANTIBODIES TO THE HUMAN IL-6 RECEPTOR |
| RU2445318C2 (ru) * | 2006-10-02 | 2012-03-20 | Ридженерон Фармасьютикалз, Инк. | Высокоаффинные антитела человека к рецептору il-4 человека |
| CA2672049C (en) * | 2006-12-08 | 2016-05-10 | Lexicon Pharmaceuticals, Inc. | Monoclonal antibodies against angptl3 |
| RU2448979C2 (ru) | 2006-12-14 | 2012-04-27 | Ридженерон Фармасьютикалз, Инк. | Антитела человека к дельта-подобному лиганду-4 человека |
| US20130064834A1 (en) | 2008-12-15 | 2013-03-14 | Regeneron Pharmaceuticals, Inc. | Methods for treating hypercholesterolemia using antibodies to pcsk9 |
| JO3672B1 (ar) | 2008-12-15 | 2020-08-27 | Regeneron Pharma | أجسام مضادة بشرية عالية التفاعل الكيماوي بالنسبة لإنزيم سبتيليسين كنفرتيز بروبروتين / كيكسين نوع 9 (pcsk9). |
| EP2216016A1 (en) | 2009-02-06 | 2010-08-11 | LEK Pharmaceuticals d.d. | Process for the preparation of a pharmaceutical composition comprising ezetimibe |
| CN101852805B (zh) | 2009-03-31 | 2015-04-01 | 浙江大学 | Angptl3作为卵巢癌的诊断标记物的用途 |
| CA2767826C (en) | 2009-07-14 | 2015-11-24 | The Scripps Research Institute | Mesenchymal stem cell differentiation using aniopoietin-like-3 |
| AU2011203986C1 (en) | 2010-01-08 | 2015-03-05 | Ionis Pharmaceuticals, Inc. | Modulation of angiopoietin-like 3 expression |
| AR087329A1 (es) * | 2011-06-17 | 2014-03-19 | Regeneron Pharma | Anticuerpos humanos contra proteina 3 de tipo angiopoietina humana |
| AU2012272970A1 (en) * | 2011-06-21 | 2014-02-06 | Alnylam Pharmaceuticals, Inc. | Angiopoietin-like 3 (ANGPTL3) iRNA compositions and methods of use thereof |
| US10111953B2 (en) | 2013-05-30 | 2018-10-30 | Regeneron Pharmaceuticals, Inc. | Methods for reducing remnant cholesterol and other lipoprotein fractions by administering an inhibitor of proprotein convertase subtilisin kexin-9 (PCSK9) |
| WO2015100394A1 (en) | 2013-12-24 | 2015-07-02 | Isis Pharmaceuticals, Inc. | Modulation of angiopoietin-like 3 expression |
| EP3137605B1 (en) | 2014-05-01 | 2020-10-28 | Ionis Pharmaceuticals, Inc. | Compositions and methods for modulating angiopoietin-like 3 expression |
| MX2017000627A (es) | 2014-07-16 | 2017-04-27 | Sanofi Biotechnology | Metodos para tratar pacientes con hipercolesterolemia familiar heterocigota (hfhe). |
| TW201713690A (zh) | 2015-08-07 | 2017-04-16 | 再生元醫藥公司 | 抗ａｎｇｐｔｌ８抗體及其用途 |
| CN108697797A (zh) | 2016-02-17 | 2018-10-23 | 瑞泽恩制药公司 | 通过施用angptl3的抑制剂治疗或预防动脉粥样硬化的方法 |
| EA201891979A1 (ru) | 2016-03-03 | 2019-01-31 | Ридженерон Фармасьютикалз, Инк. | Способы лечения пациентов с гиперлипидемией введением ингибитора pcsk9 в комбинации с ингибитором angptl3 |
| PL3439689T3 (pl) | 2016-04-08 | 2022-01-31 | Regeneron Pharmaceuticals, Inc. | Sposoby leczenia hiperlipidemii inhibitorem angptl8 i inhibitorem angptl3 |
| EP3448426A1 (en) | 2016-04-28 | 2019-03-06 | Regeneron Pharmaceuticals, Inc. | Methods for treating patients with familial hypercholesterolemia |
-
2012
- 2012-06-13 AR ARP120102099A patent/AR087329A1/es active IP Right Grant
- 2012-06-13 JO JOP/2012/0155A patent/JO3412B1/ar active
- 2012-06-14 ES ES12727767T patent/ES2699499T3/es active Active
- 2012-06-14 WO PCT/US2012/042338 patent/WO2012174178A1/en active Application Filing
- 2012-06-14 PT PT12727767T patent/PT2721065T/pt unknown
- 2012-06-14 CN CN201280038908.0A patent/CN103732624B/zh active Active
- 2012-06-14 EP EP12727767.1A patent/EP2721065B1/en active Active
- 2012-06-14 MX MX2013014345A patent/MX337644B/es active IP Right Grant
- 2012-06-14 MX MX2015017575A patent/MX361859B/es unknown
- 2012-06-14 RS RS20181508A patent/RS58310B1/sr unknown
- 2012-06-14 JP JP2014515976A patent/JP6400471B2/ja active Active
- 2012-06-14 AU AU2012271663A patent/AU2012271663B2/en active Active
- 2012-06-14 PE PE2013002804A patent/PE20141166A1/es active IP Right Grant
- 2012-06-14 PL PL12727767T patent/PL2721065T3/pl unknown
- 2012-06-14 RU RU2013155906A patent/RU2620064C2/ru active
- 2012-06-14 KR KR1020147000902A patent/KR102031007B1/ko active IP Right Grant
- 2012-06-14 CA CA2838867A patent/CA2838867C/en active Active
- 2012-06-14 LT LTEP12727767.1T patent/LT2721065T/lt unknown
- 2012-06-14 DK DK12727767.1T patent/DK2721065T3/en active
- 2012-06-14 US US13/517,662 patent/US9018356B2/en active Active
- 2012-06-14 EP EP18185031.4A patent/EP3418301A1/en not_active Withdrawn
- 2012-06-14 UA UAA201314628A patent/UA114891C2/uk unknown
- 2012-06-14 SI SI201231444T patent/SI2721065T1/sl unknown
- 2012-06-14 SG SG2013087432A patent/SG195165A1/en unknown
- 2012-06-14 TR TR2018/16591T patent/TR201816591T4/tr unknown
- 2012-06-14 MY MYPI2013004223A patent/MY160516A/en unknown
- 2012-06-15 UY UY0001039340A patent/UY39340A/es not_active Application Discontinuation
- 2012-06-15 TW TW101121453A patent/TWI644922B/zh active
- 2012-06-15 TW TW106123582A patent/TW201815822A/zh unknown
- 2012-06-15 TW TW107135714A patent/TW201920261A/zh unknown
- 2012-06-15 UY UY0001034137A patent/UY34137A/es not_active Application Discontinuation
-
2013
- 2013-11-25 IL IL229612A patent/IL229612B/en active IP Right Grant
- 2013-11-26 CR CR20130621A patent/CR20130621A/es unknown
- 2013-11-26 ZA ZA2013/08879A patent/ZA201308879B/en unknown
- 2013-12-06 NI NI201300136A patent/NI201300136A/es unknown
- 2013-12-11 CL CL2013003552A patent/CL2013003552A1/es unknown
- 2013-12-11 DO DO2013000299A patent/DOP2013000299A/es unknown
- 2013-12-11 GT GT201300306A patent/GT201300306A/es unknown
- 2013-12-13 CO CO13292222A patent/CO6821892A2/es unknown
- 2013-12-16 EC ECSP13013085 patent/ECSP13013085A/es unknown
- 2013-12-17 MA MA36579A patent/MA35190B1/fr unknown
-
2015
- 2015-03-24 US US14/667,121 patent/US9951127B2/en active Active
-
2018
- 2018-04-20 US US15/958,996 patent/US10358487B2/en active Active
- 2018-05-16 IL IL259436A patent/IL259436A/en active IP Right Grant
- 2018-07-06 JP JP2018128768A patent/JP2018166516A/ja active Pending
- 2018-12-11 CY CY181101324T patent/CY1120996T1/el unknown
- 2018-12-12 HR HRP20182098TT patent/HRP20182098T1/hr unknown
-
2019
- 2019-06-07 US US16/435,032 patent/US20190315851A1/en not_active Abandoned
-
2021
- 2021-09-01 NL NL301122C patent/NL301122I2/nl unknown
- 2021-09-06 LT LTPA2021009C patent/LTC2721065I2/lt unknown
- 2021-09-06 HU HUS2100034C patent/HUS2100034I1/hu unknown
- 2021-09-09 FI FIC20210028C patent/FIC20210028I1/fi unknown
- 2021-09-15 NO NO2021037C patent/NO2021037I1/no unknown
-
2022
- 2022-01-27 US US17/586,662 patent/US20220153825A1/en not_active Abandoned
- 2022-09-08 US US17/930,704 patent/US20220403016A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ECSP13013085A (es) | Anticuerpos anti-angptl3 y usos de los mismos | |
| AR079708A1 (es) | Anticuerpos humanos que se unen a la proteina 4 de tipo angiopoyetina humana | |
| PH12019500441A1 (en) | Monoclonal antibodies against tissue factor pathway inhibitor (tfpi) | |
| ECSP19025350A (es) | Anticuerpos monoclonales optimizados contra el inhibidor de la vía del factor tisular (tfpi) | |
| EA201500064A1 (ru) | Активаторы ampk и их применение в терапевтических целях | |
| BR112015011403A2 (pt) | uso de akkermansia para o tratamento de distúrbios metabólicos | |
| ECSP15005280A (es) | Agentes de unión de proteína de r-espondina humana (rspo3) y usos de los mismos | |
| UY32989A (es) | Coposiciones terapéuticas concentradas de fosfolípidos | |
| CO6640289A2 (es) | Composiciones de anticuerpos anti-factor de crecimiento nervioso (ngf) | |
| LT2013015A (lt) | Farmacinės kompozicijos | |
| CL2011000814A1 (es) | Uso de auna mikacina liposomal que comprende un lipido y amikacina para preparar un medicamento util para el tratamiento de un desorden pulmonar en un paciente. | |
| BR112013001299A2 (pt) | composições farmacêuticas e respectivo uso e métodos de tratamento de diabetes e doenças correlatas em paciente humano | |
| CL2013003298A1 (es) | Uso de metotrexato porque sirve para preparar un medicamento, útil en el tratamiento de enfermedades que necesiten tratamiento con un producto terapéutico que produzca autoinmunidad, administrado en un sólo ciclo. | |
| BR112016003584A8 (pt) | composições farmaceuticas e uso das mesmas para regressão de placa acelerada | |
| BR112015010039A2 (pt) | tratamento de câncer com pomalidomida em um individuo com disfunção renal | |
| AR093620A1 (es) | Anticuerpos bmp-6 | |
| BR112018000909A2 (pt) | imunoconjugados de il22 | |
| BR112015014621A2 (pt) | Anticorpos anti-h7cr | |
| BR112017001146A2 (pt) | terapia com anticorpo anti-vegfr2 para carcinoma hepatocelular | |
| BR112013032132A2 (pt) | "uso de peptidase da família calicreína, de agente que aumenta a sua expressão ou de células que apresentam expressão ou atividade de rheb reduzida para prevenção ou tratamento de diabetes e distúrbio metabólico e aumento da sensibilidade à insulina, bem como métodos para determinar se composto de teste é agente terapêutico provável no tratamento de diabetes" | |
| TN2013000490A1 (en) | Anti-angptl3 antibodies and uses thereof | |
| TH149802A (th) | โปรตีนจับเกาะแอนติเจน |